References
- Disease, G.I.f.C.O.L. 2023 GOLD report. 2023 [cited 2023 2nd Jan https://goldcopd.org/2023-gold-report-2/ https://goldcopd.org/2023-gold-report-2/]; Available from: https://goldcopd.org/2023-gold-report-2/
- Maltais F, Hamilton A, Voß F, et al. Dose determination for a fixed-dose drug combination: a phase II randomized controlled trial for tiotropium/olodaterol versus tiotropium in patients with COPD. Adv Ther. 2019;36(4):962–968. DOI:10.1007/s12325-019-00911-y
- Singh D, Jones PW, Bateman ED, et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med. 2014;14:178.
- Crim C, Watkins ML, Bateman ED, et al. randomized dose-finding study of batefenterol via dry powder inhaler in patients with COPD. int J Chron Obstruct Pulmon Dis. 2019;14:615–629.
- Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42(6):1484–1494. DOI:10.1183/09031936.00200212
- Singh D, Beier J, Astbury C, et al. The novel bronchodilator navafenterol: a phase 2a, multicentre, randomised, double-blind, placebo-controlled crossover trial in COPD. Eur Respir J. 2022;59(4):2100972. DOI:10.1183/13993003.00972-2021
- Rancati F, Linney ID, Rizzi A, et al. Discovery of a novel class of inhaled dual pharmacology muscarinic antagonist and β2 agonist (MABA) for the treatment of chronic obstructive pulmonary disease (COPD). Bioorg Med Chem Lett. 2021;41:127975.
- Aparici M, Carcasona C, Ramos I, et al. Pharmacological preclinical characterization of LAS190792, a novel inhaled bifunctional muscarinic receptor antagonist/β2-adrenoceptor agonist (MABA) molecule. Pulm Pharmacol. 2017;46:1–10.
- Aparici M, Carcasona C, Ramos I, et al. Pharmacological profile of AZD8871 (LAS191351), a novel inhaled dual m3 receptor antagonist/β2-adrenoceptor agonist molecule with long-lasting effects and favorable safety profile. J Pharmacol Exp Ther. 2019;370(1):127–136. DOI:10.1124/jpet.118.255620
- Singh D, Balaguer V, Astbury C, et al. Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator. Respir Res. 2020;21(Suppl 1):102. DOI:10.1186/s12931-020-01347-7
- Jimenez E, Astbury C, Albayaty M, et al. Navafenterol (AZD8871) in patients with mild asthma: a randomised placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of this novel inhaled long-acting dual-pharmacology bronchodilator. Respir Res. 2020;21(Suppl 1):211.
- Balaguer V, Albayaty M, Jimenez E, et al. Navafenterol (AZD8871) in healthy volunteers: safety, tolerability and pharmacokinetics of multiple ascending doses of this novel inhaled, long-acting, dual-pharmacology bronchodilator, in two phase I, randomised, single-blind, placebo-controlled studies. Respir Res. 2020;21(Suppl 1):212. DOI:10.1186/s12931-020-01474-1
- Trials, C. Efficacy, pharmacokinetics (PK), safety and tolerability study of inhaled AZD8871. 2019 [cited 2022 5th Oct 2022 https://clinicaltrials.gov/ct2/show/NCT02971293?term=AZD8871&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT02971293?term=AZD8871&draw=2&rank=1]; Available from: https://clinicaltrials.gov/ct2/show/NCT02971293?term=AZD8871&draw=2&rank=1
- Singh D, Fuhr R, Jimenez L, et al. A randomized trial of dual-acting bronchodilator AZD8871 For chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2019;199(10):1282–1284. DOI:10.1164/rccm.201812-2345LE
- ClinicalTrials. A single inhalation dose study to assess efficacy, pharmacokinetics (PK), safety and tolerability of AZD8871 in patients with long-term lung diseases. 2018 [cited 2022 21st Sep https://clinicaltrials.gov/ct2/show/NCT03645434 https://clinicaltrials.gov/ct2/show/NCT03645434]; Available from: https://clinicaltrials.gov/ct2/show/NCT03645434
- Zeneca A Astra zeneca respiratory and immunology pipeline (as of 10th November 2022). 2022 https://www.astrazeneca.com/our-therapy-areas/pipeline.html https://www.astrazeneca.com/our-therapy-areas/pipeline.html; Available from: https://www.astrazeneca.com/our-therapy-areas/pipeline.html
- Insight A Navafenterol - AstraZeneca. 2021 [cited 2022 5th Dec https://adisinsight.springer.com/drugs/800043459 https://adisinsight.springer.com/drugs/800043459]; Available from: https://adisinsight.springer.com/drugs/800043459
- Martinez FJ, Fabbri LM, Ferguson GT, et al. Baseline symptom score impact on benefits of glycopyrrolate/formoterol metered dose inhaler in COPD. Chest. 2017;152(6):1169–1178. DOI:10.1016/j.chest.2017.07.007